SG-5035

SG-5035 is an oral cyclic peptide antagonist targeting **interleukin-17A (IL-17A)**, currently in development by **Sungening** (Suzhou Sungening Bio-Tech). As a lead candidate from Sungening's proprietary oral cyclic peptide platform, SG-5035 is engineered to achieve high metabolic stability and intestinal permeability, addressing the historical limitations of peptide drugs in oral delivery. By selectively binding to IL-17A and inhibiting its interaction with the IL-17 receptor, SG-5035 aims to provide a convenient oral treatment option for chronic inflammatory conditions such as **psoriasis**, **psoriatic arthritis**, and **ankylosing spondylitis**. The program is often cited as a representative example of the company's ability to develop macrocyclic peptides against extracellular protein-protein interaction (PPI) targets that are difficult to address with traditional small molecules.